Sense Biodetection: John Bishop
Sense Biodetection appointed John Bishop as a non-executive director.
Bishop, Cepheid's CEO from 2002 until its acquisition by Danaher in 2016, will play a pivotal strategic role at Sense as the company rapidly scales up production and distribution of its first products, including its COVID-19 test, Veros SARS-CoV-2.
At Cepheid, Bishop was instrumental in accelerating the firm's growth as a molecular diagnostics company. He oversaw the successful launch and commercialization of its GeneXpert and GeneXpert Xpress systems.